Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunityBio
In search of a differentiated approach, candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
- Other Names / Subsidiaries